John R Burnett

List of Publications by Citations

122 papers	3,502 citations	32 h-index	55 g-index
131 ext. papers	3,997 ext. citations	5 avg, IF	5.37 L-index

#	Paper	IF	Citations
122	The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. *Atherosclerosis*, **2007**, 193, 445-8	3.1	271
121	Phenylketonuria: an inborn error of phenylalanine metabolism. *Clinical Biochemist Reviews*, **2008**, 29, 31-41	7.3	180
120	HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. *Circulation Research*, **2015**, 116, 1133-42	15.7	172
119	Lipid disorders and mutations in the APOB gene. *Clinical Chemistry*, **2004**, 50, 1725-32	5.5	154
118	Familial hypercholesterolaemia: a model of care for Australasia. *Atherosclerosis Supplements*, **2011**, 12, 221-63	1.7	153
117	Vitamin E in human health and disease. *Critical Reviews in Clinical Laboratory Sciences*, **2008**, 45, 417-50	9.4	116
116	Common and rare ABCA1 variants affecting plasma HDL cholesterol. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1983-9	9.4	113
115	Genetic determinants of hepatic steatosis in man. *Journal of Lipid Research*, **2011**, 52, 593-617	6.3	90
114	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. *Current Opinion in Lipidology*, **1997**, 8, 138-45	4.4	85
113	Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 2589-600	9.4	83
112	Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. *Critical Reviews in Clinical Laboratory Sciences*, **2005**, 42, 515-45	9.4	75
111	A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. *Journal of Biological Chemistry*, **2003**, 278, 13442-52	5.4	70
110	Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia. *Journal of Biological Chemistry*, **2007**, 282, 24270-83	5.4	58
109	Genetic analysis of familial hypercholesterolaemia in Western Australia. *Atherosclerosis*, **2012**, 224, 430-4	3.1	56
108	Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 1884-91	9.4	56
107	Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. *International Journal of Cardiology*, **2015**, 201, 633-8	3.2	55
106	Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. *Journal of Lipid Research*, **1999**, 40, 1317-1327	6.3	55

105	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. *Atherosclerosis*, **2015**, 239, 93-100	3.1	54
104	Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. *Critical Reviews in Clinical Laboratory Sciences*, **2011**, 48, 1-18	9.4	50
103	MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 181-9	6.4	49
102	Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. *Pathology*, **2019**, 51, 148-154	1.6	49
101	Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. *Journal of the American College of Cardiology*, **2014**, 63, 2365-73	15.1	48
100	Mipomersen, an antisense apolipoprotein B synthesis inhibitor. *Expert Opinion on Investigational Drugs*, **2011**, 20, 265-72	5.9	48
99	The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. *Endocrinology*, **1999**, 140, 5293-302	4.8	46
98	Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein. *Circulation Research*, **2015**, 116, 193-205	15.7	44
97	Opportunistic screening for familial hypercholesterolaemia via a community laboratory. *Annals of Clinical Biochemistry*, **2012**, 49, 534-7	2.2	44
96	Cardiovascular disease and osteoporosis: is there a link between lipids and bone?. *Annals of Clinical Biochemistry*, **2002**, 39, 203-10	2.2	44
95	Anti-PCSK9 therapies for the treatment of hypercholesterolemia. *Expert Opinion on Biological Therapy*, **2013**, 13, 429-35	5.4	40
94	Update on primary hypobetalipoproteinemia. *Current Atherosclerosis Reports*, **2014**, 16, 423	6	39
93	Common and rare gene variants affecting plasma LDL cholesterol. *Clinical Biochemist Reviews*, **2008** , 29, 11-26	7.3	38
92	Liver dysfunction and steatosis in familial hypobetalipoproteinemia. *Clinical Chemistry*, **2005**, 51, 266-9	5.5	34
91	Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. *Critical Reviews in Clinical Laboratory Sciences*, **2002**, 39, 89-137	9.4	34
90	Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. *Journal of Clinical Lipidology*, **2016**, 10, 1329-1337.e3	4.9	32
89	Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. *Vascular Health and Risk Management*, **2012**, 8, 651-9	4.4	32
88	A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 1704-1714	5.6	30

87	Clinical utility gene card for: Abetalipoproteinaemia. *European Journal of Human Genetics*, **2012**, 20,	5.3	30
86	Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia. *Clinical Chemistry*, **2006**, 52, 1339-45	5.5	30
85	The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 1906-14	9.4	29
84	Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1474-8	5.6	28
83	Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. *Clinica Chimica Acta*, **1999**, 286, 231-42	6.2	28
82	Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. *Current Opinion in Molecular Therapeutics*, **2009**, 11, 681-91		28
81	Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. *Journal of Lipid Research*, **2003**, 44, 943-52	6.3	26
80	Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2014**, 28, 387-403	6.5	24
79	Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. *Clinical Cardiology*, **2018**, 41, 378-384	3.3	23
78	Screening for familial hypercholesterolaemia. *Pathology*, **2012**, 44, 122-8	1.6	23
77	Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?. *Clinical Chemistry*, **2019**, 65, 1258-1266	5.5	22
76	Lipids, lipoproteins, atherosclerosis and cardiovascular disease. *Clinical Biochemist Reviews*, **2004**, 25, 2	7.3	22
75	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. *Nature Reviews Endocrinology*, **2016**, 12, 467-84	15.2	22
74	Novel missense MTTP gene mutations causing abetalipoproteinemia. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2014**, 1842, 1548-54	5	21
73	Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner. *Atherosclerosis*, **2014**, 234, 469-72	3.1	21
72	Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. *Expert Opinion on Investigational Drugs*, **2006**, 15, 1337-51	5.9	21
71	High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations. *Annals of Clinical Biochemistry*, **2008**, 45, 170-6	2.2	20
70	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. *Heart Lung and Circulation*, **2021**, 30, 324-349	1.8	20

69	Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. *Lipids and Lipid Metabolism*, **1998**, 1393, 63-79		19
68	Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3732-3739	5.6	17
67	High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency. *Atherosclerosis*, **2016**, 253, 7-14	3.1	17
66	Dalcetrapib , a cholesteryl ester transfer protein modulator. *Expert Opinion on Investigational Drugs*, **2012**, 21, 1427-32	5.9	16
65	The role of patient registries for rare genetic lipid disorders. *Current Opinion in Lipidology*, **2018**, 29, 156-162	4.4	15
64	Protein kinase C controls vesicular transport and secretion of apolipoprotein E from primary human macrophages. *Journal of Biological Chemistry*, **2013**, 288, 5186-97	5.4	15
63	Tangier disease: update for 2020. *Current Opinion in Lipidology*, **2020**, 31, 80-84	4.4	13
62	A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency. *Clinica Chimica Acta*, **2009**, 409, 136-9	6.2	13
61	The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats. *Current Atherosclerosis Reports*, **2018**, 20, 31	6	13
60	Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. *IDrugs: the Investigational Drugs Journal*, **2007**, 10, 805-13		13
59	The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory. *Clinica Chimica Acta*, **2015**, 448, 18-21	6.2	11
58	Parent-child genetic testing for familial hypercholesterolaemia in an Australian context. *Journal of Paediatrics and Child Health*, **2018**, 54, 741-747	1.3	11
57	Interpretative comments specifically suggesting specialist referral increase the detection of familial hypercholesterolaemia. *Pathology*, **2016**, 48, 463-6	1.6	11
56	Recent developments in the genetics of LDL deficiency. *Current Opinion in Lipidology*, **2013**, 24, 111-5	4.4	11
55	Update on the diagnosis, treatment and management of rare genetic lipid disorders. *Pathology*, **2019**, 51, 193-201	1.6	11
54	Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. *Current Opinion in Molecular Therapeutics*, **2006**, 8, 461-7		11
53	Clinical features and genetic analysis of three patients with severe hypertriglyceridaemia. *Annals of Clinical Biochemistry*, **2014**, 51, 485-9	2.2	10
52	Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB). *European Journal of Human Genetics*, **2012**, 20,	5.3	10

51	Clinical utility gene card for: Sitosterolaemia. *European Journal of Human Genetics*, **2017**, 25,	5.3	9
50	Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia. *Clinica Chimica Acta*, **2013**, 421, 121-5	6.2	9
49	Anacetrapib, a cholesteryl ester transfer protein inhibitor. *Expert Opinion on Investigational Drugs*, **2012**, 21, 103-9	5.9	9
48	A novel missense HGD gene mutation, K57N, in a patient with alkaptonuria. *Clinica Chimica Acta*, **2009**, 403, 254-6	6.2	9
47	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 275-81	4	8
46	Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia. *Current Opinion in Investigational Drugs*, **2006**, 7, 850-6		8
45	Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia. *Free Radical Biology and Medicine*, **2015**, 88, 59-62	7.8	7
44	Running interference to lower cholesterol. *Lancet, The*, **2014**, 383, 10-12	40	7
43	Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia. *Clinica Chimica Acta*, **2020**, 510, 211-215	6.2	7
42	Eflucimibe. Pierre Fabre/Eli Lilly. *Current Opinion in Investigational Drugs*, **2003**, 4, 347-51		7
41	Clinical utility gene card for: Tangier disease. *European Journal of Human Genetics*, **2017**, 25,	5.3	6
40	Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB)--Update 2014. *European Journal of Human Genetics*, **2015**, 23,	5.3	6
39	Clinical utility gene card for: Abetalipoproteinaemia--Update 2014. *European Journal of Human Genetics*, **2015**, 23,	5.3	6
38	Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E1484-90	5.6	6
37	The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2005**, 1738, 10-8	5	6
36	"Milky" urine: a case of chyluria. *Medical Journal of Australia*, **2004**, 180, 89	4	6
35	Therapeutic considerations for postprandial dyslipidaemia. *Diabetes, Obesity and Metabolism*, **2001**, 3, 143-56	6.7	6
34	Familial hypobetalipoproteinaemia: a rare presentation to the lipid clinic. *Medical Journal of Australia*, **1993**, 159, 272-4	4	6

33	Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. *Heart Lung and Circulation*, **2021**, 30, 372-379	1.8	6
32	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. *Atherosclerosis*, **2020**, 298, 52-57	3.1	5
31	Familial hypobetalipoproteinemia in a Turkish family with hereditary spastic paraplegia. *Clinica Chimica Acta*, **2008**, 390, 152-5	6.2	5
30	Documenting family history in children with hypercholesterolaemia: A lost opportunity. *Journal of Paediatrics and Child Health*, **2017**, 53, 470-473	1.3	4
29	Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient with familial hypercholesterolaemia. *Annals of Clinical Biochemistry*, **2009**, 46, 420-2	2.2	4
28	FM-VP4 Forbes Medi-Tech. *Current Opinion in Investigational Drugs*, **2003**, 4, 1120-5		4
27	Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). *Atherosclerosis*, **2021**,	3.1	3
26	A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. *Clinical Genetics*, **2020**, 97, 257-263	4	3
25	Novel APOB missense variants, A224T and V925L, in a black South African woman with marked hypocholesterolemia. *Journal of Clinical Lipidology*, **2016**, 10, 604-9	4.9	2
24	Lipoprotein metabolism in an apoB-80 familial hypobetalipoproteinemia heterozygote. *Clinical Biochemistry*, **2016**, 49, 720-722	3.5	2
23	A novel missense SMPD1 gene mutation, T460P, and clinical findings in a patient with Niemann-Pick disease type B presenting to a lipid disorders clinic. *Annals of Clinical Biochemistry*, **2014**, 51, 615-8	2.2	2
22	Lipoprotein lipase deficiency presenting with neonatal perianal abscesses. *BMJ Case Reports*, **2016**, 2016,	0.9	2
21	Avasimibe Pfizer. *Current Opinion in Investigational Drugs*, **2002**, 3, 1328-33		2
20	Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. *Pathology*, **2020**, 52, 447-452	1.6	1
19	Estimating LDL ApoB: infomania or clinical advance?. *Clinical Chemistry*, **2008**, 54, 782-4	5.5	1
18	Isolated brachydactyly type E and idiopathic pancreatitis in a patient presenting to a lipid disorders clinic. *BMJ Case Reports*, **2017**, 2017,	0.9	1
17	Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata. *Annals of Clinical Biochemistry*, **2021**, 58, 153-156	2.2	1
16	Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia. *Journal of Paediatrics and Child Health*, **2021**,	1.3	1

15	Molecular Genetics of Hypobetalipoproteinaemia and Abetalipoproteinaemia		1
14	Torcetrapib + atorvastatin (Pfizer). *Current Opinion in Investigational Drugs*, **2005**, 6, 944-50		1
13	Filiarial chyluria with nephrotic-range proteinuria and associated hypoalbuminaemia and hypogammaglobulinaemia secondary to bilateral lymphorenal fistulae. *BMJ Case Reports*, **2017**, 2017,	0.9	0
12	Publication metrics: it really is all about the numbers. *Pathology*, **2021**, 53, 561-563	1.6	0
11	l-asparaginase-induced biochemical toxicities in young adults with acute lymphoblastic leukaemia and T-lymphoblastic lymphoma. *Pathology*, **2021**, 53, 924-926	1.6	0
10	Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand. *Journal of Clinical Apheresis*, **2021**, 36, 48-58	3.2	0
9	Lipoprotein Lipase Deficiency in an Infant With Chylomicronemia, Hepatomegaly, and Lipemia Retinalis. *Global Pediatric Health*, **2017**, 4, 2333794X17715839	1.2	
8	SPG11 mutation in a Turkish familial hypobetalipoproteinemia family with hereditary spastic paraplegia. *Clinica Chimica Acta*, **2015**, 445, 1	6.2	
7	New therapies for familial hypercholesterolemia. *Expert Opinion on Therapeutic Patents*, **2006**, 16, 349-361	6.8	
6	Familial hypercholesterolaemia: a look back, a look ahead. *Medical Journal of Australia*, **2005**, 183, 222-223	4	
5	Incidental diagnosis of LPL deficiency in an infant presenting with an acute respiratory infection.. *Clinica Chimica Acta*, **2022**, 529, 1-1	6.2	
4	Genetic Abetalipoproteinaemia and Hypobetalipoproteinaemia. *Contemporary Endocrinology*, **2015**, 251-266	2.9	
3	The lipid profile in children prior to isotretinoin therapy: an opportunity to detect familial hypercholesterolaemia. *Pathology*, **2021**, 53, 288-290	1.6	
2	Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia. *IDrugs: the Investigational Drugs Journal*, **2006**, 9, 495-9		
1	Disorders of Lipoprotein Metabolism **2022**, 1035-1055		